Article
Novel ACE2-IgG1 fusions with improved <i>in vitro</i> and <i>in vivo</i> activity against SARS-CoV2
2020-06-15
Abstract excerpt
SARS-CoV2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. This fusion protein contained a LAL...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b3fd0d5e-4e34-56db-9378-d136740a9e9d
- DOI
- 10.1101/2020.06.15.152157
